TranSYS Training School 24th November 10.00

Prof Adil Mardinoglu

Professor of Systems Biology

KTH-Royal Institute of Technology & Kings College London

Tuesday 24th November 2020  10.00 CET

Keynote lecture: The use of systems biology in treatment of liver diseases


To develop novel strategies for prevention and treatment as well as to gain detailed insights about the underlying molecular mechanisms of liver diseases, it is vital to study the biological functions of liver and its interactions with other tissues and gut microbiota. Biological networks can provide a scaffold for studying biological pathways operating in the liver in connection with disease development in a systematic manner. In my presentation, I will present our recent work where biological networks have been employed to identify the reprogramming in liver physiology in response to NASH/NAFLD. I will further discuss how this mechanistic modelling approach can contribute to the discovery of biomarkers and identification of drug targets which may lead to design of targeted and effective treatment strategies.

Key references:

1) A. Mardinoglu et al, Systems biology in hepatology: approaches and applications, Nature Reviews Gastroenterology & Hepatology, 15, 365–377, 2018. *Corresponding author.

2) A. Mardinoglu et al, An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans, Cell Metabolism, 27, 559-571.e5, 2018.

3) A. Mardinoglu* et al, Personalized genome-scale modeling identifies NAD+ and glutathione metabolism as a target for treatment of NAFLD, Molecular Systems Biology, 13:916, 2017.


Professor Adil Mardinoglu is an expert in the field of Systems Medicine, Systems Biology, Computational Biology and Bioinformatics. He has been recruited as a Professor of Systems Biology in Center for Host-Microbiome Interactions, King’s College London, UK where he leads a computational group. He also works as group leader in Science for Life Laboratory (Scilifelab), KTH-Royal Institute of Technology in Sweden and led a team of 25 researchers working in the area of computational biology, experimental biology and drug development to develop new treatment strategies for Metabolic diseases, Neurodegenerative diseases and certain type of cancers.